[Adherence with XXXX inhibitor therapy, by continuously taking nonsteroidal anti-inflammatory drugs].

@entity1 @entity32 @entity7080 @entity309
AIM: To estimate the impact of adherence with @entity7080 inhibitor (PPI) therapy on the incidence of nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathy ( @entity32 ) in @entity1 with @entity309 ( @entity309 ). SUBJECTS AND METHODS: PPI pharmacotherapy adherence was estimated using the Medication Adherence Questionnaire (MAQ) in 92 @entity1 with @entity309 , including 32 @entity1 did not take a PPI and 60 used a PPI. The groups were matched for age, disease duration, and used NSAIDs. All those asked underwent video esophagogastroduodenoscopy. RESULTS: According to the data of MAQ survey, low, moderate, and high adherence subgroups could be identified among the @entity1 treated with a PPI. @entity32 was detected in 43.8% of the @entity1 taking no PPI, in 50% of those with low PPI treatment adherence, in 12.5% with moderate adherence, and in 4.5% with high adherence. In the @entity1 with low adherence to PPI therapy, @entity32 was recorded 11 times more frequently than in those with high adherence (c2 = 7.77; p = 0.005). This condition occurred in 28.6% of the @entity1 taking NSAID without preventively using a PPI in the absence of risk factors for @entity32 . CONCLUSION: Only 36.7% @entity1 who had been recommended to use a PPI for the prevention of @entity32 strictly observed their doctor's directions. Low PPI pharmacotherapy adherence may serve as an additional risk factor for @entity32 in @entity1 in whom preventive antisecretory therapy used in combination with NSAID is indicated.
